New filings and stem cell deal hold out promise for MS
This article was originally published in Scrip
Executive Summary
The recent US and EU filings for Novartis' fingolimod and the announcement of a UK collaboration on stem cell research are welcome developments for multiple sclerosis patients and doctors awaiting potential new treatments for this intractable and distressing disease.